Active Trials at UCLA Health Alpha Clinic

Trial Sponsor Disease Indication Clinical Trial Name ClinicalTrials.gov Identifier IRB # Phase STATUS CT.GOV
CIRM Blood Disorders Clinical Research Study of Autologous Bone Marrow Transplantation for Sickle Cell Disease (SCD) Using Bone Marrow CD34+ Cells Modified With the Lenti/G-βAS3-FB Lentiviral Vector NCT02247843 13-000288 Phase 1/2 Recruiting
Merck; CIRM Cancer A Phase I Trial of Intratumoral Administration of CCL21-gene Modified Dendritic Cell (DC) Combined With Intravenous Pembrolizumab Foradvanced NSCLC NCT03546361 17-000174 Phase 1 Recruiting
CIRM; NEI Vision Loss Stem Cell-Based Therapy for Limbal Stem Cell Deficiency NCT03957954 19-001056 Phase 1 Recruiting
Astellas Pharma, Inc. Vision Loss A Phase 1b, Multicenter, Dose Escalation, Evaluation of Safety and Tolerability of ASP7317 forGeographic Atrophy Secondary to Age-related Macular Degeneration NCT03178149 17-000835 Phase 1 Recruiting
CIRM, UCLA Immune Disease Efficacy And Safety Of Cryopreserved Autologous Mobilized Peripheral Blood CD34+ Hematopoietic Stem And Progenitor Cells Transduced Ex Vivo With The EFS-ADA Lentiviral Vector In Patients With Severe Combined Immune Deficiency Due To Adenosine Deaminase Deficiency NCT05432310 21-001814 Phase 1/2 Recruiting
Neurona Therapeutics Inc. Neurological Disorders A First-In-Human (FIH) Study of Inhibitory Interneurons (NRTX-1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE) NCT05135091 21-001132 Phase 1/2 Recruiting
CIRM, NHLBI, UCSF Blood Disorders Transplantation of CRISPR-CAS9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patient with Severe Sickle Cell Disease NCT04774536 21-001649 Phase 1/2 Recruiting
COH, Metastatic Melanoma Alliance Cancer Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors NCT04119024 19-001145 Phase 1 Recruiting
CIRM, NHLBI, Children's Hospital Boston Blood Disorders A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (GRASP, BMT CTN 2001) (GRASP) NCT05353647 22-000665 Phase 1 Active, not recruiting